Steven Cohen Intercept Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

$39.3 Billion
Q1 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$12.53 - $21.71 $2.08 Million - $3.61 Million	-166,300 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$11.61 - $16.11 $16.2 Million - $22.4 Million	-1,392,883 Reduced 89.33%	166,300 $2.06 Million
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $17.5 Million - $28.2 Million	1,431,883 Added 1124.81%	1,559,183 $21.8 Million
Q2 2022 Aug 15, 2022	BUY	$11.23 - $19.59 $570,484 - $995,172	50,800 Added 66.41%	127,300 $1.76 Million
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $5.85 Million - $7.79 Million	-437,700 Reduced 85.12%	76,500 $1.25 Million

Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $2.63 Million - $3.6 Million	-184,500 Reduced 26.41%	514,200 $8.38 Million
Q3 2021 Nov 15, 2021	BUY	$12.99 - $20.47 $9.08 Million - $14.3 Million	698,700 New	698,700 $10.4 Million
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $50.4 Million - $78.2 Million	-648,278 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $52.2 Million - $68.6 Million	568,078 Added 708.33%	648,278 $72.5 Million
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $6.88 Million - $10.1 Million	80,200 New	80,200 $8.08 Million
Q2 2018 Aug 14, 2018	SELL	$60.0 - $85.67 $16.9 Million - $24.2 Million	-281,900 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$52.72 - $67.25 $13.4 Million - $17.1 Million	254,400 Added 925.09%	281,900 $17.3 Million
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $1.75 Million - $2.18 Million	-30,000 Reduced 52.17%	27,500 $1.61 Million
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $3.28 Million - $6.83 Million	57,500	57,500 $3.34 Million

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account